An atlas for clinical target volume definition, including elective nodal irradiation in definitive radiotherapy of biliary cancer

SILVIA BISELLO¹, MATTEO RENZULLI², MILLY BUWENGE¹, LUCIA CALCULLI², GIUSEPPINA SALLUSTIO³, GABRIELLA MACCHIA⁴, FRANCESCO DEODATO⁵, GIANCARLO MATTIUCCI⁶, SILVIA CAMMELLI¹, ALESSANDRA ARCELLI¹, LUCIA GIACCHERINI¹, FRANCESCO CELLINI⁵, GIOVANNI BRANDI⁶, SARA GUERRI², SAVINO CILLA⁷, RITA GOLFIERI², LORENZO FUCCIO⁸, ALESSIO G. MORGANTI¹* and ALESSANDRA GUIDO¹*

¹Radiation Oncology Unit, Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi Hospital; ²Radiology Unit, Department of Diagnostic and Preventive Medicine, S. Orsola-Malpighi Hospital, I-40138 Bologna; ³Radiology Unit; ⁴Radiation Oncology Unit, Catholic University of The Sacred Heart, I-86100 Campobasso; ⁵Radiation Oncology Department, Sacred Heart Catholic University, I-00168 Rome; ⁶Department of Experimental, Diagnostic and Specialty Medicine, ‘L. e. A. Seragnoli’ Institute of Hematology and Medical Oncology, S. Orsola-Malpighi Hospital, I-40138 Bologna; ⁷Medical Physics Unit ‘Giovanni Paolo II’ Foundation, Catholic University of the Sacred Heart, I-86100 Campobasso; ⁸Department of Medical and Surgical Sciences, University of Bologna, I-40138 Bologna, Italy

Received June 7, 2018; Accepted October 31, 2018

DOI: 10.3892/ol.2018.9774

Abstract. Radiotherapy (RT) is a treatment option for advanced biliary tract cancer (BTC), often combined with sequential and/or concurrent chemotherapy. The use of modern RT techniques requires accurate clinical target volume (CTV) definition and delineation. However, guidelines for CTV delineation in BTC are lacking. Therefore, the aim of this study was to propose a computer tomography (CT) atlas for CTV definition of BTC. We previously proposed guidelines to define the nodal CTV (CTV-N) in BTC. In this study, based on a literature analysis, we defined the margins to be added to the gross tumor volume (GTV; subclinical and microscopic disease) to define the primary tumor CTV (CTV-T). An abdominal contrast enhanced planning CT scan was performed on three different patients with unresectable intrahepatic cholangiocarcinoma (CC), extrahepatic CC and gallbladder cancer. The GTV and anatomical reference structures were outlined on CT images. Then, based on our guidelines, the CTV-T and CTV-N were delineated and merged to define the final CTV in the three patients. An atlas, showing the defined CTV, was generated from the reference CT images to illustrate the CTV for intra-hepatic CC, extra-hepatic CC and gallbladder cancer. This atlas can be used as an aid for CTV definition in patients with BTC treated with modern RT techniques.

Introduction

Biliary tract cancers (BTC) are rare malignancies, representing <1% of all human cancers (1). Incidence is low in Western countries with ~0.3-3.5/100,000 cases/year, while in Asia and particularly in China, Thailand, and both North and South Korea, it is higher due to an increased frequency of liver flukes (2,3). BTC arise from biliary epithelium and almost 90% of cases are adenocarcinomas. BTC are classified as: Intrahepatic cholangiocarcinomas (CCs), extrahepatic CC, and gallbladder carcinoma (GC).

Complete resection (R0) is the only potentially curative treatment option. However, due to the advanced disease at diagnosis, more than half of the patients are not surgical candidates (4).

Radiotherapy (RT) generally combined with concurrent and/or sequential chemotherapy is considered as a treatment option for locally advanced BTC by international guidelines (4,5). In fact, several studies on these tumors demonstrated the efficacy of chemoradiation, sometimes followed by a brachytherapy (BT) boost for symptoms palliation, local control (LC) and overall survival (OS) improvement (6-9).

However, although RT is considered a treatment option for locally advanced BTC, there is no consensus on clinical target volume (CTV) definition. Recently, Marinelli et al (10) published a review on the incidence of metastases in the
different regional nodal stations of patients with BTC. Based on that analysis, we proposed guidelines for the definition of the nodal CTV (CTV-N) in intrahepatic CC, extrahepatic CC, and GC (10).

The aim of the present study was to provide supplementary literature data concerning the microscopic spread of the primary lesion and to suggest a proper CTV definition of the primary tumor (CTV-T). Furthermore, our objective was to define a general CTV by merging these evidence-based CTV-T and CTV-N. Finally, we aimed to present an atlas for locally advanced BTC delineation.

**Materials and methods**

**Nodal clinical target volume (CTV-N).** The definition of the CTV-N was described in our previous analysis (10) and is only briefly summarized in the present study in Tables I-III.

All lymph nodes nomenclature was based on the 3rd English Edition of the Classification of BTC established by the Japanese Society of Hepato-Biliary-Pancreatic Surgery (11). We included in the hepatoduodenal lymph nodes (LN), also those around both portal vein and hepatic artery (groups 12a1, 12a2, 12pl and 12p2), for anatomic contiguity of the structures in the hepatic hilum. Furthermore, we assumed the posterior pancreaticoduodenal LN (group 13) being similar to retropancreatic LN. Finally, we respected the definition of left and right paracardial LNs based on the gastric LNs contouring Atlas, from Wo et al (12).

In this CTV-N delineation, a 10 mm margin of soft tissue around vessels, ligament and ducts was suggested, based on several literature data (12-15), without overlap with radiosensitive structures (duodenum, liver, small bowel, stomach). Only for para-cardials nodes and lesser gastric curvature nodes, the suggested target was defined without any further expansion to preserve the surrounding OARs.

**Primary tumor CTV**

*Literature review.* To define the CTV-T we studied the microscopic extension of different sub sites of biliary cancers based on available literature data.

*Intrahepatic CC.* Intrahepatic CC usually appears as a homogenous mass with irregular but well-defined margins (mass-forming type). Rarely, they present as small lesions with diffuse bile duct thickening (periductal infiltrating type) or can grow intraductally, showing only a duct ectasia with variable visible mass (intraductal type) (16). Based on the study of Bi et al (17), the microscopic extension from the macroscopic disease ranged from 0.4 to 8.0 mm. From the comparison between pathological evaluation of the surgical specimens and radiological images, they concluded that the imaging-based gross tumor volume (GTV) should be

---

**Table I. CTV for intrahepatic cholangiocarcinoma.**

| Delineation type                        | JSHBPS classification | Recommended margins                                                                 |
|----------------------------------------|-----------------------|--------------------------------------------------------------------------------------|
| **Tumor delineation**                  |                       | GTV + 10 mm radially                                                                |
| Intrahepatic cholangiocarcinoma        | -                     |                                                                                     |
| Lymph node group, nodes delineation    |                       |                                                                                     |
| Hepatoduodenal ligament lymph nodes    | 12                    | 10 mm margin around the segment of portal vein from the confluence between the right and left hepatic ducts and the upper border of the pancreas |
| Common hepatic artery lymph nodes      | 8                     | 10 mm margin around the common hepatic artery                                        |
| Para-aortic lymph nodes                | 16                    | 10 mm margin around the abdominal aorta, from the diaphragmatic aortic hiatus to the upper border of the origin of the inferior mesenteric artery |
| Posterior pancreaticoduodenal lymph nodes | 13                   | 10 mm around the posterior pancreaticoduodenal artery                                |
| Left gastric artery lymph nodes        | 7                     | 10 mm around the trunk of the left gastric artery                                     |
| Lesser gastric curvature lymph nodes   | 3                     | The area around the lesser curvature of the stomach                                   |
| Right paracardial lymph nodes          | 1                     | The narrowed anatomic space identified between gastric cardia and the liver, extending posteriorly to the aorta and inferiorly to the lesser curvature LNs |
| Left paracardial lymph nodes           | 2                     | The anatomic space defined medially by the gastric fundus, anteromedially by the visceral peritoneum, posteriorly by the spleen, superiorly by the hemi diaphragm, and inferiorly by the great curvature LNs |

Lymph node nomenclature is based on the 3rd English Edition of Classification of biliary tract cancers established by the JSHBPS. The anatomical structures of interest and the abdominal vessels of reference were identified for each lymph node region. JSHBPS, Japanese Society of Hepato-Biliary-Pancreatic Surgery; CTV, clinical target volume; GTV, gross tumor volume.
expanded by 9.8 mm to include any microscopic disease with 100% accuracy. **Extrahepatic CCs.** Extrahepatic CCs show different behavior based on the histological type. They can be described as

| Delineation type                        | JSHBPS classification | Recommended margins                                                                 |
|----------------------------------------|-----------------------|-------------------------------------------------------------------------------------|
| Tumor delineation                      |                        |                                                                                     |
| Extrahepatic cholangiocarcinoma         | -                     | GTV + 25 mm on the proximal direction of the bile duct + 20 mm on the distal direction + 15 mm radially in all directions |
| Lymph node group, nodes delineation    |                        |                                                                                     |
| Hepatoduodenal ligament lymph nodes    | 12                    | 10 mm margin around the segment of portal vein from the confluence between the right and left hepatic ducts and the upper border of the pancreas |
| Left gastric artery lymph nodes        | 7                     | 10 mm around the trunk of the left gastric artery                                      |
| Common hepatic artery lymph nodes      | 8                     | 10 mm margin around the common hepatic artery                                         |
| Para-aortic lymph nodes                | 16                    | 10 mm margin around the abdominal aorta, from the diaphragmatic aortic hiatus to the upper border of the origin of the inferior mesenteric artery |
| Posterior pancreaticoduodenal lymph nodes | 13                   | 10 mm around the posterior pancreaticoduodenal artery                                |
| Anterior pancreaticoduodenal lymph nodes | 17                   | 10 mm margin around the anterior pancreaticoduodenal artery                          |
| Peri-choledochal nodes                 | 12b2                  | 10 mm margin around the choledochal duct                                             |

Lymph node nomenclature is based on the 3rd English Edition of Classification of biliary tract cancers established by the JSHBPS. The anatomical structures of interest and the abdominal vessels of reference were identified for each lymph node region. JSHBPS, Japanese Society of Hepato-Biliary-Pancreatic Surgery; CTV, clinical target volume; GTV, gross tumor volume.

| Delineation type                        | JSHBPS classification | Recommended margins                                                                 |
|----------------------------------------|-----------------------|-------------------------------------------------------------------------------------|
| Tumor delineation                      |                        |                                                                                     |
| Gallbladder carcinoma                  | -                     | GTV + 25 mm radially in hepatic direction + gallbladder residual volume              |
| Lymph node group, nodes delineation    |                        |                                                                                     |
| Hepatoduodenal ligament lymph nodes    | 12                    | 10 mm margin around the segment of portal vein from the confluence between the right and left hepatic ducts and the upper border of the pancreas |
| Common hepatic artery lymph nodes      | 8                     | 10 mm margin around the common hepatic artery                                         |
| Para-aortic lymph nodes                | 16                    | 10 mm margin around the abdominal aorta, from the diaphragmatic aortic hiatus to the upper border of the origin of the inferior mesenteric artery |
| Posterior pancreaticoduodenal lymph nodes | 13                   | 10 mm around the posterior pancreaticoduodenal artery                                |
| Anterior pancreaticoduodenal lymph nodes | 17                   | 10 mm margin around the anterior pancreaticoduodenal artery                          |
| Peri-choledochal nodes                 | 12b2                  | 10 mm margin around the choledochal duct                                             |
| Cystic duct lymph nodes                | 12c                   | 10 mm around the cystic duct                                                        |

Lymph node nomenclature is based on the 3rd English Edition of Classification of biliary tract cancers established by the JSHBPS. The anatomical structures of interest and the abdominal vessels of reference were identified for each lymph node region. JSHBPS, Japanese Society of Hepato-Biliary-Pancreatic Surgery; CTV, clinical target volume; GTV, gross tumor volume.
papillary, nodular, and sclerosing type. Papillary types often show an intraluminal growth, whereas nodular and sclerosing types appear to spread longitudinally along the submucosal layer. Chang et al (18) reported a microscopic spread of papillary, nodular, and sclerosing types of 15.6, 10.0, and 15.6 mm in 90% of cases, respectively. For the latter two histological types, the length of microscopic tumor spread negatively correlates with macroscopic tumor size. Ebata et al (19) reported 10 mm intramural extension spread in all directions but observed that considering the superficial involvement, surgical margins of 20 mm could be assured to be negative proximally in 89.0% of cases and distally in 93.8%.

Gallbladder carcinoma (GC). GC presents an early invasion through the subserosal layer, due to the thin wall and lack of a muscularis mucosae (20). Depending on the type of growth, Kondo et al (21) classified GC as: i) Hepatic bed type, where the mass penetrates through the gallbladder bed; ii) hepatic hilum type, with infiltration of the hepatic hilum from the neck of the gallbladder; iii) bed and hilum type, with massive invasion; iv) lymph node type, with only lymphatic involvement; v) cystic duct type and vi) localized type. There is lack of analyses in literature on microscopic extension evaluation. Only Ogura et al (20) demonstrated an average microscopic extension in most aggressive cases of advanced stage GC of 15.2 mm (range: 2 to 25 mm).

Primary tumor CTV definition. Based on previously reported literature data, we defined the CTV-T for the three different sub sites.

Intrahepatic CC. Based on the study of Bi et al (17), for intrahepatic CC we added 10 mm radially to the GTV for CTV-T delineation (Table I).

Extrahepatic CC. Based on Chang et al (18) and Ebata et al data (19), our suggested CTV-T includes the GTV plus 25 mm proximally and 20 mm distally through the bile duct, and 15 mm radially in all other directions (Table II).

GC. Based on Ogura et al (20), for optimal control of microscopic disease we suggest including in the CTV-T the GTV plus 25 mm radially in the hepatic direction and any gallbladder residual volume (Table III).

Overall CTV definition. The definition of the overall CTV was achieved by merging the CTV-N as defined in our previous analysis (10), and the CTV-T as described in the previous paragraph. The CTV-N definition was performed by including for every sub site, all lymph node stations with an incidence of 5% of metastasis (10).

Atlas design. Three patients with locally advanced unresectable intrahepatic CC, extrahepatic CC, and GC were enrolled in this study. Three different CTVs were defined according to the method described above. Patients were immobilized in a customized Alpha Cradle. GTV was delineated using contrast enhanced planning computer tomography (CT) scans. Contouring of each anatomical structure close to the tumor was performed by experienced radiologists (MR, LC, GS, SG, RG) and radiation oncologists (GM, FD, GCM, FC, AG).

Results
The CTV-N, CTV-T and overall CTV are described in Tables I-III and shown in the atlas (Figs. 1-3) regarding intrahepatic CC, extrahepatic CC, and GC, respectively. In the atlas, the GTV and the main anatomical structures
Discussion

Locally advanced unresectable disease is the most common presentation of BTC. Some studies demonstrated that combined-modality therapy based on chemoradiation +/- BT...
Boost could reduce pain and improve LC, biliary decompression, and OS (6-9). In a recent retrospective study on 37 patients with unresectable extrahepatic CC treated with chemoradiation, 1-year LC and OS rates were 90 and 59%, respectively (8).

Unfortunately, the results recorded in recent years (22-27) did not show a significant improvement of patients’ outcome, which remain similar to those recorded in previous decades (6-9). An improvement in the clinical results could derive from innovative combinations with systemic therapies and/or from a more intensive use of most advanced RT techniques (IMRT, VMAT, IGRT). These could allow the delivery of higher RT doses without worsening radio-induced toxicity. However, these increasingly precise and conformed techniques require clearer guidelines for the contouring of the target and our atlas can represent a first proposal in this direction.

Our study presents some limitations mainly due to the paucity of data concerning BTC microscopic and nodal spread. In fact, the information found in the analyzed studies were mainly generic, without differentiation based on tumor stage and sub-sites, nodal stage, and site of positive nodes. Therefore, we were unable to give specific indications about CTV definition based on the different stages and sub-sites of the three main BTCs. It represents a limitation of our results and an area for future work in this issue.

Obviously, the guidelines illustrated in this atlas should be adapted to individual patients. Particularly, careful attention must be given to inclusion in the target of any suspected or positive node, even if outside the proposed CTV.

Further pathological studies and sentinel node analysis would be useful to better understand the microscopic and lymphatic spread of these tumors based on tumor stage and nodal involvement.

The recommendations summarized in our atlas could be supplemented in future by pattern of failure studies where patients undergoing concurrent chemoradiation are closely followed using modern imaging techniques to define the most frequent sites of disease relapse. Studies of this type could lead to a more advanced version of the atlas.

We should underline that our study has been performed according to scientific literature where an atlas for target delineation is presented using the images of a single patient or as in this case, a few exemplary patients with different tumor sites. Clearly, this modality cannot give us information on the feasibility of large-scale application of the atlas. In particular, we cannot estimate the impact of this type of target contouring on OARs irradiation. Therefore, further prospective studies testing feasibility and efficacy of this CTV delineation modality are justified.

In the last decade, there were no significant improvements in the outcome of patients with biliary tumors treated with chemoradiation. Therefore, innovative prospective trials are needed to improve clinical outcomes. This atlas, while providing practical guidelines for CTV delineation, could represent the basis to design these new studies.

Acknowledgements

The abstract has previously been presented as an oral communication at XXVII Congresso Nazionale Associazione Italiana Radioterapia Oncologia, Rimini, Italy, November 11-13, 2017 and at the 37th Annual meeting of the European Society for Radiotherapy & Oncology, Barcelona, Spain, April 20-24, 2018 as an electronic poster.

Funding

No funding was received.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.
The authors declare that they have no competing interests.

Ethics approval and consent to participate

All patients provided written informed consent for the use of their images. The study protocol was approved by the Ethics Committee of 'Giovanni Paolo II' Foundation, Catholic University of the Sacred Heart, Campobasso, Italy.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Shaib T and El-Serag HB: The epidemiology of cholangiocarcinoma. Semin Liver Dis 24: 115-125, 2004.
2. Bragazzi MC, Cardinale V, Carpino G, Venere R, Semeraro R, Gentile R, Gaudio E and Alvaro D: Cholangiocarcinoma: Epidemiology and risk factors. Transl Gastrointest Cancer 1: 21-32, 2012.
3. Siegel R, Ma J, Zou Z, and Jemal A: Cancer statistics, 2014. CA Cancer J Clin 64: 9-29, 2014.
4. NCCN guideline version 2018, Hepatobiliary Cancers. http://www.nccn.org/professionals/physician_gls/default.aspx. Accessed March 17, 2018.
5. Valle JW, Bemabath I, Khan SA, Huguet F, Gruenberger T and Arnold D: ESMO Guidelines Committee: Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 27 (Suppl 5): v28-v37, 2016.
6. Mattiucci GC, Autorino R, D’Agostino GR, Deodato F, Macchia G, Perri V, Tringali A, Morganti AG, Mutignani M and Valentini V: Chemoradiation and brachytherapy in extrahepatic bile duct carcinoma. Crit Rev Oncol Hematol 90: 58-67, 2014.
7. Zevallos D, Clemente G, Mattiucci GC, Macchia G, Costamagna G, Juiliani F, Smaniutto D, Luiz S, Valentini V, Mutignani M, et al: Chemoradiation and brachytherapy in biliary tract cancer: Long-term results. Int J Radiat Oncol Biol Phys 64: 483-488, 2006.
8. Ghafouri AP, Nelson JW, Willett CG, Chon J, Tyler DS, Hurwitz HI, Urnès HE, Morse MA, Clough RW and Czito BG: Radiotherapy in the treatment of patients with unresectable extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys 81: 654-659, 2011.
9. Chopra S, Mathew AS, Engineer R and Shrivastava SK: Positioning high-dose radiation in multidisciplinary management of unresectable cholangiocarcinomas: Review of current evidence. Indian J Gastroenterol 33: 401-407, 2014.
10. Marinelli I, Guido A, Fuccio I, Ferrari A, Panni V, Giaccherini L, Arcelli A, Ercolani G, Brandi G, Cammelli S, et al: Clinical target volume in biliary carcinoma: A systematic review of pathological studies. Ant Res 37: 955-961, 2017.
11. Miyazaki M, Ohtsuka M, Miyakawa S, Nagino M, Yamamoto M, Kokudo N, Sano K, Endo I, Unno M, Chijiwa K, et al: Classification of biliary tract cancer trends established by the Japanese Society of Hepato-Biliary-Pancreatic Surgery: 3rd edition. J Hepatobiliary Pancreat Sci 22: 181-196, 2015.